48LOW

NAN

NANOSONICS FPO [NAN]
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Healthcare · ASX Small Cap
$3.7000 +1.9%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical66
Catalyst50
Sentiment50
Fundamental87
Momentum41
Risk Gate40
Get alerts when NAN's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track NAN — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Knocking on the door of resistance — if it punches through, things could get interesting
  • Beating the Small Ords index — relative strength of 1.21, so it's outpacing the pack
  • Volume-price trend suggests distribution — sellers may be sneaking out while price holds
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Cash positive / operating cashflow positive
  • Moderate P/S ratio (5.4x)
  • Moderate revenue growth (+9%)
  • Piotroski F-Score strong (8/9, low-confidence approx)
  • EPS estimates revised upward (+3pts)
  • Very high short interest (11.9%)
  • CANSLIM A: Strong annual earnings CAGR (77%)
  • CANSLIM I: Institutional ownership (62%)
  • Sentiment is mixed — no strong consensus either way
  • Days to cover very high (33.8)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Earnings declining (-1% QoQ)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 23% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.64%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NAN
"What's driving NAN's score?" "How does NAN compare to peers?" "Key risks for NAN?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Update - Notification of buy-back - NAN
NONE Update - Notification of buy-back - NAN
NONE Update - Notification of buy-back - NAN

Recent ASX Announcements

2026-03-22 Update - Notification of buy-back - NAN
2026-03-19 Update - Notification of buy-back - NAN
2026-03-18 Update - Notification of buy-back - NAN
2026-03-18 Application for quotation of securities - NAN
2026-03-17 Update - Notification of buy-back - NAN

Key Metrics

$1.1B
Market Cap
1.1M
Avg Volume
1.0x
Vol Ratio
$3.21 — $5.08
52-Week Range
11.9%
Short Interest
N/A
Cash Runway
10.1%
ROE
9.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSdecliningEPS Growth: -1%
AAnnual EarningspassCAGR: 77%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 84%
LLeader vs LaggardlaggardRS: -2
IInstitutional SponsorshippassInst: 62%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #48 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:NAN vs ATXNAN vs PNVNAN vs IMM
Scout Pro — Deeper Analysis for NAN
Try Pro free for 30 days
Share this analysis

Track NAN and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required